Bristol-Myers Squibb Company (BMY) Q1 2026 (USD): EPS 1.58 (exp. 1.42), revenue 11.5bln (exp. 10.9bln). Reaffirms 2026 guidance with total revenue & adj. EPS trending toward upper end of ranges

Bristol-Myers Squibb's Q1 2026 results surpassed expectations on both EPS and revenue, indicating strong performance and growth in the key drug Eliquis.

Newsquawk StaffPublished On the live feed at 13 more headlines followed before this page went public
Newsquawk headlinesUTC

BoE MPR FORECASTS: split under three scenarios

BOE STATEMENT: BoE maintains Bank Rate at 3.75%, as expected, in 8-1 vote (exp. 9-0); Pill votes to raise Bank Rate by 25bps to 4%

Bristol-Myers Squibb Company (BMY) Q1 2026 (USD): EPS 1.58 (exp. 1.42), revenue 11.5bln (exp. 10.9bln). Reaffirms 2026 guidance with total revenue & adj. EPS trending toward upper end of ranges

Quanta Services Inc. (PWR) Q1 2026 (USD): Adj. EPS 2.68 (exp. 2.04), Revenue 7.9bln (exp. 7.00bln), Adj. EBITDA 686.4mln (exp. 572.4mln)

L3Harris Technologies Inc (LHX) Q1 2026 (USD): EPS 2.72 (exp. 2.53), Revenue 5.74bln (exp. 5.42bln)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Eliquis revenue 4.14bln, up 16%.
  • FY worldwide Eliquis Revenue growth of 10% - 15%.
Context

The reaffirmation of 2026 guidance, trending towards the upper end of revenue and EPS ranges, suggests confidence in continuing momentum, which could positively influence investor sentiment and stock performance in the pharmaceuticals sector.

Related headlines

The whole workspace, free to try.

Try it free